FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Arbuckle Stuart A (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE (Street)						Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 04/15/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) EVP\Chief Commercial Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
BOSTON (City)			72210 Zip)		-										Form filed by More than One Reporting Person			
		Tabl	e I - I	Non-Deriv	ative/	Sec	uritie	s A	cquir	ed, D	Disposed o	of, or I	3enefici	ially	Owne	ed		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					2A. Deemed Execution Date, if any (Month/Day/Year)		·			Acquired (A) or (D) (Instr. 3, 4 and		5) Secu Bene		ficially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(1130.4)
Common Stock 04/15/2019					19	9			S ⁽¹⁾		2,592	D	\$180.9	80.95(2)(3)		36,272	D	
Common	Stock			04/15/20	19				S ⁽¹⁾		2,712	D	\$182.2	.29 ⁽³⁾⁽⁴⁾ 33,560 D				
Common Stock 04/15/201					19	.9			S ⁽¹⁾		320	D	\$183.	\$183.61		33,240	D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	vative Conversion urity or Exercise Price of Derivative Security Date (Month/Day/Year) (Month/Day/Year) Execution Date, if any (Month/Day/Year)		4. Transa Code 8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instrand 5	rities ired osed	Expi (Mor	ration hth/Day	//Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Number of Title Shares				9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$180.95 (range \$180.47 to \$181.33).
- 3. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$182.29 (range \$181.86 to \$182.54).

Remarks:

/s/ Omar White, Attorney-in-

04/17/2019

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.